Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128466 | 0.86 | SSTR4 (0.39) | SSTR4NAMPTNLRP3HDAC3HDAC1 | |
| SCHEMBL29843420 | 0.76 | SSTR4 (0.34) | SSTR4 | |
| SCHEMBL20517822 | 0.76 | SSTR4 (0.34) | SSTR4 | |
| SCHEMBL16501844 | 0.74 | SSTR4 (0.41) | SSTR4NLRP3HDAC3HDAC1HDAC2 | |
| SCHEMBL20525185 | 0.73 | SSTR4 (0.32) | SSTR4 | |
| SCHEMBL20517408 | 0.71 | CYP17A1 (0.38) | NAMPTHDAC3NCOR2 | |
| SCHEMBL24595056 | 0.71 | GABRA1 (0.34) | — | |
| SCHEMBL6501824 | 0.70 | CACNA1G (0.41) | SSTR4 | |
| SCHEMBL1921998 | 0.70 | PTGDR2 (0.47) | SSTR4 | |
| SCHEMBL31226440 | 0.69 | HDAC3 (0.37) | SSTR4NAMPTNLRP3HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | SSTR4 2514/4885NAMPT 671/4885NLRP3 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.